These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38706271)

  • 21. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease.
    Malek-Ahmadi M; Beach TG; Zamrini E; Adler CH; Sabbagh MN; Shill HA; Jacobson SA; Belden CM; Caselli RJ; Woodruff BK; Rapscak SZ; Ahern GL; Shi J; Caviness JN; Driver-Dunckley E; Mehta SH; Shprecher DR; Spann BM; Tariot P; Davis KJ; Long KE; Nicholson LR; Intorcia A; Glass MJ; Walker JE; Callan M; Curry J; Cutler B; Oliver J; Arce R; Walker DG; Lue LF; Serrano GE; Sue LI; Chen K; Reiman EM
    PLoS One; 2019; 14(6):e0217566. PubMed ID: 31237877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies.
    Thomas AJ; Donaghy P; Roberts G; Colloby SJ; Barnett NA; Petrides G; Lloyd J; Olsen K; Taylor JP; McKeith I; O'Brien JT
    Psychol Med; 2019 Feb; 49(3):396-402. PubMed ID: 29692275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
    Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND
    Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential diagnosis of MCI with Lewy bodies and MCI due to Alzheimer's disease by visual assessment of occipital hypoperfusion on SPECT images.
    Nakata T; Shimada K; Iba A; Oda H; Terashima A; Koide Y; Kawasaki R; Yamada T; Ishii K
    Jpn J Radiol; 2024 Mar; 42(3):308-318. PubMed ID: 37861956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam).
    Feldman HH; Luchsinger JA; Léger GC; Taylor C; Jacobs DM; Salmon DP; Edland SD; Messer K; Revta C; Flowers SA; Jones KS; Koulman A; Yarasheski KE; Verghese PB; Venkatesh V; Zetterberg H; Durant J; Lupo JL; Gibson GE;
    PLoS One; 2024; 19(5):e0302998. PubMed ID: 38809849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies.
    Wesnes KA; Aarsland D; Ballard C; Londos E
    Int J Geriatr Psychiatry; 2015 Jan; 30(1):46-54. PubMed ID: 24737460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.
    Shimada H; Shinotoh H; Hirano S; Miyoshi M; Sato K; Tanaka N; Ota T; Fukushi K; Irie T; Ito H; Higuchi M; Kuwabara S; Suhara T
    Mov Disord; 2013 Feb; 28(2):169-75. PubMed ID: 23225334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease.
    Alam J; Blackburn K; Patrick D
    J Prev Alzheimers Dis; 2017; 4(4):273-278. PubMed ID: 29181493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Imaging Characteristics Associated with Color Vision Impairment in Lewy Body Disease.
    Unger RH; Flanigan PM; Khosravi M; Leverenz JB; Tousi B
    J Alzheimers Dis; 2019; 72(4):1233-1240. PubMed ID: 31683482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.
    Gauthier S; Aisen PS; Ferris SH; Saumier D; Duong A; Haine D; Garceau D; Suhy J; Oh J; Lau W; Sampalis J
    J Nutr Health Aging; 2009 Jun; 13(6):550-7. PubMed ID: 19536424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
    Silva-Rodríguez J; Labrador-Espinosa MA; Moscoso A; Schöll M; Mir P; Grothe MJ;
    Brain; 2023 Nov; 146(11):4520-4531. PubMed ID: 37284793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies.
    Nedelska Z; Ferman TJ; Boeve BF; Przybelski SA; Lesnick TG; Murray ME; Gunter JL; Senjem ML; Vemuri P; Smith GE; Geda YE; Graff-Radford J; Knopman DS; Petersen RC; Parisi JE; Dickson DW; Jack CR; Kantarci K
    Neurobiol Aging; 2015 Jan; 36(1):452-61. PubMed ID: 25128280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study.
    Yoon JH; Kim M; Moon SY; Yong SW; Hong JM
    J Neurol Sci; 2015 Aug; 355(1-2):174-9. PubMed ID: 26076880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
    Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
    Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S
    PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer's disease.
    Marui W; Iseki E; Kato M; Akatsu H; Kosaka K
    Acta Neuropathol; 2004 Aug; 108(2):121-8. PubMed ID: 15235805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies.
    Sarro L; Senjem ML; Lundt ES; Przybelski SA; Lesnick TG; Graff-Radford J; Boeve BF; Lowe VJ; Ferman TJ; Knopman DS; Comi G; Filippi M; Petersen RC; Jack CR; Kantarci K
    Brain; 2016 Oct; 139(Pt 10):2740-2750. PubMed ID: 27452602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood mRNA Expression in Alzheimer's Disease and Dementia With Lewy Bodies.
    Donaghy PC; Cockell SJ; Martin-Ruiz C; Coxhead J; Kane J; Erskine D; Koss D; Taylor JP; Morris CM; O'Brien JT; Thomas AJ
    Am J Geriatr Psychiatry; 2022 Sep; 30(9):964-975. PubMed ID: 35283023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.